Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

More abnormal cells linked to poorer ASCT outcomes in MDS

Key clinical point: A higher percentage of cytogenetically abnormal cells at transplant is linked to worse posttransplant survival in patients with myelodysplastic syndromes.

Major finding: MDS patients with greater than 60% cytogenetically abnormal cells at transplant had inferior overall survival, compared with MDS patients with less than 30% abnormal cells (hazard ratio 2.478; P = .040) in multivariable analysis.

Study details: A study of 109 adults with MDS who underwent allogeneic stem cell transplant during January 2000–December 2016.

Disclosures: The researchers reported having no relevant financial disclosures.